Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia

European Journal of Clinical Investigation

Volumn 38, Issue 1, 2008, Pages 11-16

  Puccetti, L ^a   Bruni, F ^a   Pasqui, A L ^a   Pastorelli, M ^a   Ciani, F ^b   Palazzuoli, A ^a   Acampa, M ^a   Auteri, A ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Acute cardiovascular events; Atorvastatin; Hypercholesterolaemia; LOX 1; NOS

Indexed keywords

ANTICOAGULANT AGENT; ATORVASTATIN; C REACTIVE PROTEIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PADGEM PROTEIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ACTIVITY; DRUG DOSE TITRATION; ENZYMATIC ASSAY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; THROMBOCYTE ACTIVATION;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CORONARY ARTERY DISEASE; FEMALE; FIBRINOLYTIC AGENTS; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE; POLYMORPHISM, GENETIC; PYRROLES; SCAVENGER RECEPTORS, CLASS E;

EID: 37349021357     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01891.x     Document Type: Article

References (15)

1. Packard C. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. Atherosclerosis Suppl 2006 7: 21 9.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomised placebo-controlled trial. Lancet 2002 360:7 22.
3. Kajinami K, Akao H, Polisecki E, Schaefer EJ. Pharmacogenomics of statin responsiveness. Am J Cardiol 2005 96 (Suppl 65K 70K.
4. Puccetti L, Pasqui AL, Auteri A, Bruni F. Mechanisms for antiplatelet action of statins. Curr Drug Targets Cardiovasc Haematol Disord 2005 5:121 6.
5. Puccetti L, Pasqui AL, Pastorelli M, Ciani F, Palazzuoli A, Gioffrè WR et al. 3′UTR/T polymorphisms of lectin-like oxidized-LDL receptor-1 (LOX-1) is associated with modified antiplatelet activity of atorvastatin in hypercholesterolemic subjects. Atherosclerosis 2005 183:322 8.
6. Mango R, Clementi F, Borgiani P, Forleo GB, Federici M, Contino G et al. Association of single nucleotide polymorphisms in the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction. J Med Genet 2003 40:933 6.
7. 298-Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999 100:1515 20.
8. Puccetti L, Pasqui Al, Bruni F, Pastorelli M, Ciani F, Palazzuoli A et al. Lectin-like oxidized-LDL rerecptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment. Int J Cardiol 2006 October 12 [Epub ahead of print].
9. Expert Panel on Detection, Evaluation Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adults treatment panel III). JAMA 2001 285:2486 97.
10. Expert Committee on the Diagnosis Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003 26 (Suppl. 1 S5 S20.
11. The seventh report of the Joint National Committee on prevention, detection evaluation treatment of high blood pressure. The JNC 7 report. JAMA 2003 289:2560 72.
12. Jeerooburkhan N, Jones LC, Bujac S, Cooper JA, Miller GJ, Vallance P et al. Genetic and environmental determinants of plasma nitrogen oxides and risk of ischemic heart disease. Hypertension 38:1054 61.
13. Damas JK, Puccetti L, Aukrust P. Early Anti-thrombotic and anti-inflammatory actions of statins and fibrates. Time for adjuvant therapy in acute coronary syndromes? Thromb Haemost 2005 94:1 3.
14. Khera A, De Lemos JA, Peshock RM, Lo HS, Stanek HG, Murphy SA et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 2006 113:38 43.
15. Fitzmaurice G. The meaning and interpretation of interaction. Nutrition 2000 16:313 4.